These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23220098)

  • 21. The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study.
    Paolicelli D; Manni A; Iaffaldano A; Di Lecce V; D'Onghia M; Iaffaldano P; Trojano M
    Eur J Clin Pharmacol; 2016 Aug; 72(8):1025-9. PubMed ID: 27251359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
    Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
    Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.
    Sørensen PS; Deisenhammer F; Duda P; Hohlfeld R; Myhr KM; Palace J; Polman C; Pozzilli C; Ross C;
    Eur J Neurol; 2005 Nov; 12(11):817-27. PubMed ID: 16241970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
    Lam R; Farrell R; Aziz T; Gibbs E; Giovannoni G; Grossberg S; Oger J
    J Immunol Methods; 2008 Jul; 336(2):113-8. PubMed ID: 18511063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.
    Najafi B; Ghaderi H; Jafari M; Najafi S; Ahmad Kiadaliri A
    Glob J Health Sci; 2014 Oct; 7(2):139-47. PubMed ID: 25716386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
    Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R
    Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.
    Abolfazli R; Hosseini A; Gholami Kh; Javadi MR; Torkamandi H; Emami S
    ISRN Neurol; 2012; 2012():786526. PubMed ID: 22928117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ
    J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
    Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA; Calabresi PA; Chakraborty S; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Imrey PB; Ivancic DM; Mandell BF; Perryman JE; Scott TF; Skaramagas TT; Zhang H;
    Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
    Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
    Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.
    Hermanrud C; Ryner M; Luft T; Jensen PE; Ingenhoven K; Rat D; Deisenhammer F; Sørensen PS; Pallardy M; Sikkema D; Bertotti E; Kramer D; Creeke P; Fogdell-Hahn A;
    J Immunol Methods; 2016 Mar; 430():1-9. PubMed ID: 26779831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis.
    Bellomi F; Muto A; Palmieri G; Focaccetti C; Dianzani C; Mattei M; Jaber A; Antonelli G
    New Microbiol; 2007 Jul; 30(3):241-6. PubMed ID: 17802901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS; Koch-Henriksen N; Bendtzen K
    Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
    Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
    Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
    Bojar M; Zajac M; Meluzínová E; Houžvičková E; Libertinová J; Lišková P; Mat'oška V; Nyč O; Mináriková M
    Mult Scler; 2010 Dec; 16(12):1529-30; author reply 1531-2. PubMed ID: 20829243
    [No Abstract]   [Full Text] [Related]  

  • 40. Quality of life in relapsing-remitting multiple sclerosis patients receiving CinnoVex compared with Avonex.
    Hatam N; Bastani P; Shahtaheri RS
    J Res Pharm Pract; 2016; 5(3):181-5. PubMed ID: 27512709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.